Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
GlycoMimetics (GLYC) has issued an update.
GlycoMimetics, Inc. announced significant findings from its Phase 3 trial of uproleselan, targeting relapsed/refractory acute myeloid leukemia, and held a live webcast to discuss these outcomes. While detailed results were shared, this information is for disclosure purposes and will not be considered officially filed or integrated into prior or future securities filings, unless explicitly stated.
Find detailed analytics on GLYC stock on TipRanks’ Stock Analysis page.
